Health Technology, Healthcare Analytics
businesswire | September 27, 2023
Weave a leading all-in-one experience platform for small and medium-sized healthcare businesses, announced a new partnership with Affirm the payment network that empowers consumers and helps merchants drive growth. Now available to thousands of Weave’s customers, this collaboration provides flexible payment options for eligible patients, making it easier for them to access and afford the care they need.
By partnering with Affirm, Weave customers can offer their patients pay-over-time financing with as low as 0% APR. Affirm is directly integrated with Weave payments, so patients can apply to pay with Affirm in a matter of seconds, and spread out their payments over time, easing the burden of upfront costs and providing an additional payment option for dental, optometry, veterinary, or medical practices. This partnership will not only benefit patients but also allow healthcare practices to receive payments quicker than before.
“Collecting payments is one of the most important parts of the patient's journey. A smooth and efficient payment process can help to create a positive patient experience, build trust, and encourage repeat business, which is why we are excited to partner with Affirm,” said Branden Neish, Chief Product & Technology Officer of Weave. “By providing more flexible and affordable payment options, we are empowering patients to take control of their healthcare and ensuring that cost doesn’t prevent them from receiving the care they need.”
By expanding the payment options available to patients, Weave and Affirm aim to remove barriers to care and ensure everyone has access to the healthcare services they need. The partnership reflects the shared commitment of both companies to make patients’ payment experience more seamless and revolutionize the way healthcare practices handle payments.
“By partnering with Weave, thousands of healthcare practices can now seamlessly add Affirm’s transparent and flexible payment options at checkout,”
said Wayne Pommen, Chief Revenue Officer of Affirm.
Patients are eager to pay over time without junk fees, late fees, or compounding interest, and now these businesses can address that demand.
[Source – Business Wire]
About Weave
Weave is the all-in-one experience platform for small- and medium-sized healthcare businesses. From the first phone call to the final invoice and every touchpoint in between, Weave connects the entire customer journey. Weave’s software solutions transform how local businesses attract, communicate with and engage customers to grow their business. Weave has set the bar for Utah startup achievement & work culture. In the past year, Weave has been named a G2 leader in Patient Engagement, Optometry, Dental Practice Management and Patient Relationship Management software.
About Affirm
Affirm’s mission is to deliver honest financial products that improve lives. By building a new kind of payment network — one based on trust, transparency and putting people first — we empower millions of consumers to spend and save responsibly, and give thousands of businesses the tools to fuel growth. Unlike most credit cards and other pay-over-time options, we show consumers exactly what they will pay up front, never increase that amount, and never charge any late or hidden fees.
Read More
Health Technology
CareView Communications | September 13, 2023
CareView Communications, Inc., a prominent provider of integrated virtual care solutions for the healthcare sector, has announced the introduction of its most recent milestone in patient care technology through the unveiling of Software Version 5.10. This release incorporates many cutting-edge features and improvements meticulously crafted to empower healthcare professionals and enhance patient results.
Software Release 5.10 introduces a range of significant enhancements, beginning with the seamless integration of CareView with Get Well, a leading patient engagement platform. This integration facilitates bidirectional video communication, ultimately elevating patient engagement, education, and overall satisfaction.
Additionally, a new Universal Dashboard has been introduced. This internal tool plays a crucial role in optimizing solutions. It leverages hospital utilization data along with machine learning algorithms to provide predictive analytics and enables in-depth analyses, significantly enhancing the overall offerings.
Derek del Carpio, CareView's VP of Product Development, stated,
At CareView, we continuously strive to provide innovative solutions that redefine patient care. Software Release 5.10 is a testament to our commitment to advancing virtual care technology and enhancing the well-being of patients.
[Source: Business Wire]
Further, substantial improvements have been applied to the Virtual Sitting feature, empowering CareView Controllers to manipulate associated views through EquipmentView and introducing Night Mode in SitterView to reduce eye strain, thus enhancing both patient monitoring flexibility and safety. Virtual Nursing has also undergone notable refinements, enabling the virtual Registered Nurse to mute participants during TeleCareView encounters, facilitating participants' easy transition between viewing fellow participants and shared screens, and granting healthcare providers the capability to blur backgrounds in TeleCareView, thereby fostering a more professional and focused virtual interaction environment.
CareView maintains a steadfast commitment to fostering collaboration with healthcare providers to elevate patient safety, optimize clinical processes, and enhance overall patient care quality. Introducing this latest software release further underscores CareView's unwavering dedication to providing hospital teams with innovative virtual care solutions to meet their evolving needs.
About CareView Communications
CareView, leveraging predictive technology and purpose-built hardware, has forged partnerships with more than 200 hospitals to tackle pressing staffing issues and elevate patient safety through its platform. The company collaborates closely with its hospital partners to deliver tailored virtual care strategies that improve patient outcomes and foster a sustainable healthcare ecosystem.
Read More
Healthcare Analytics
Xenex | September 11, 2023
United States Food and Drug Administration (USFDA) has issued a De Novo authorization to Xenex Disinfection Services, Inc. (Xenex) for its LightStrikeTM+ device, an advanced high-intensity, broad-spectrum ultraviolet (UV) light robot.
The LightStrike+ devices are designed for microbial reduction on non-critical medical device surfaces in healthcare environments, following manual cleaning and disinfection practices. They are authorized for use in various healthcare settings, including unoccupied operating rooms and hospital rooms. These devices have an impressive track record, with over 1,200 healthcare facilities worldwide employing LightStrike robots for over 37 million cycles.
The new LightStrike+ device, capable of microbial reduction in as little as 2 minutes, represents the culmination of over a decade of knowledge accumulation from healthcare facilities' best practices, supported by 45 peer-reviewed studies demonstrating its safety and effectiveness, a portfolio of 193 patents, and unparalleled technical and epidemiological expertise.
Dr. Mark 'Tuck' Stibich, Xenex's Founder and Chief Scientific Officer, emphasized the long-standing collaboration with healthcare partners spanning more than a decade to enhance patient safety and public health.
As an infectious diseases epidemiologist, Dr. Stibich expressed concern about antibiotic resistance within hospital environments and the potential for FDA authorization to facilitate the broader adoption of the LightStrike+ tool in combating pathogens.
Perilous pathogens persist on surfaces within healthcare facilities, notwithstanding diligent manual cleaning endeavors. The LightStrike+ robot employs a xenon lamp to generate high-intensity pulsed UV light, which effectively diminishes the presence of these pathogens on surfaces and plays a pivotal role in interrupting the transmission chain from one patient or healthcare worker to another. Xenex's FDA authorization is substantiated by comprehensive testing conducted on more than 10,000 samples of vegetative bacteria and Clostridiodes difficile (C. diff) spores.
This authorization establishes a novel medical device product classification, with the LightStrike+ robot being its inaugural and sole product. It is a landmark in the FDA's regulatory framework for UV robots designed to diminish pathogens on non-porous, frequently touched surfaces within healthcare settings.
Furthermore, Xenex's Chief Executive Officer, Morris Miller, acknowledged the challenges hospitals face when evaluating UV technologies, citing the prevalence of unverified and exaggerated claims by some manufacturers. He underscored the significance of FDA authorization in instilling confidence among hospital decision-makers, assuring them of the accuracy and validation of Xenex's claims regarding the LightStrike+ device.
Numerous world-renowned hospitals, such as HonorHealth, Mayo Clinic, MD Anderson Cancer Center, Ochsner Health System, Stanford Health Care, and Texas Health Resources, have integrated LightStrike robots into their comprehensive disinfection strategies.
About Xenex
Xenex is a global leader in pioneering strategies and solutions grounded in UV technology. Its fundamental mission revolves around enabling its partners to safeguard lives and reduce human suffering by eliminating the dangerous microorganisms that cause infections. The company benefits from substantial support from renowned investors, including EW Healthcare Partners, Piper Sandler, Malin Corporation, Battery Ventures, Targeted Technology Fund II, Tectonic Ventures, and RK Ventures.
Read More
Health Technology, Digital Healthcare
Aspect Imaging | September 25, 2023
Aspect Imaging, a global leader in MRI systems for neonatal patients, has been awarded an Innovative Technology contract by Vizient, the nation's largest provider -driven healthcare performance improvement company. This contract recognizes the unique qualities of Aspect Imaging's Embrace Point of Care Neonatal MRI System and its potential to bring improvements to the healthcare industry. The Embrace Point of Care Neonatal MRI System is designed specifically for the imaging needs of prematureand newborn infants, making it a critical tool in neonatal intensive care units (NICUs).
The Embrace is the world's first FDA-cleared and CE-approved MRI system for neonatal patients. It is designed to be placed directly within NICUs, overcoming the size and risk limitations associated with adult MRI scanners. The system includes features such as a temperature-controlled patient bed and a Whisper Quiet sound profile to meet the specific care needs of neonatal patients. This technology enables safer and more accessible MRI imaging for fragile neonatal patients and provides critical information to the clinical care team.
Chief Commercial Officer at Aspect Imaging, Wendy Slatery, stated,
It is an honor to have the Embrace recognized by the clinical experts at Vizient, as an Innovative Technology, and an exciting opportunity to bring valuable solutions to Vizient customers. We are looking forward to working with Vizient members seeking to expand and elevate neurocritical care of the smallest patients while reducing patient risks and staff time associated with transporting newborns to a traditional MRI. The Embrace MRI gives the neonatal medical team access to information from the life’s first hours and throughout the patient’s time in the NICU, on which critical care decisions will be based.
[Source: Business Wire]
Vizient's provider customer-led councils recommended the Embrace system for an Innovative Technology contract after evaluating its potential to enhance clinical care, patient safety, and healthcare worker safety, or improve business operations in healthcare organizations. The recognition and award of this contract highlight the potential of the Embrace Point of Care Neonatal MRI System to improve neurocritical care for the smallest patients while reducing risks associated with transporting newborns to traditional MRI facilities.
About Aspect Imaging
Aspect Imaging, a pioneering force in the field, stands as the global frontrunner in crafting and advancing compact MR imaging systems tailored for both research and clinical use. Their groundbreaking technology centers on compact, high-performance permanent magnets, introducing transformative MRI solutions to tackle unmet requirements in research and medical contexts. These innovations ensure the delivery of the finest quality images, whether at the benchtop or in point-of-care scenarios.
Read More